Latest Insider Transactions at Bristol Myers Squibb CO (BMY)
This section provides a real-time view of insider transactions for Bristol Myers Squibb CO (BMY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BRISTOL MYERS SQUIBB CO to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BRISTOL MYERS SQUIBB CO's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2024
|
Phil M Holzer SVP and Controller |
SELL
Open market or private sale
|
Direct |
700
-5.62%
|
$38,500
$55.62 P/Share
|
|
Nov 01
2024
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
BUY
Open market or private purchase
|
Direct |
1,830
+2.86%
|
$98,820
$54.67 P/Share
|
|
Nov 01
2024
|
Christopher S. Boerner Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,488
-1.43%
|
$80,352
$54.32 P/Share
|
|
Nov 01
2024
|
Christopher S. Boerner Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
55
-0.05%
|
-
|
|
Nov 01
2024
|
Christopher S. Boerner Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,964
+2.77%
|
-
|
|
Oct 02
2024
|
Cari Gallman EVP, Corporate Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
1,648
-24.72%
|
$87,344
$53.76 P/Share
|
|
Oct 02
2024
|
Cari Gallman EVP, Corporate Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
4,558
+40.61%
|
-
|
|
Aug 01
2024
|
Cari Gallman EVP, Corporate Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
384
-15.4%
|
$18,432
$48.17 P/Share
|
|
Aug 01
2024
|
Cari Gallman EVP, Corporate Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,061
+29.85%
|
-
|
|
Apr 01
2024
|
Karin Shanahan EVP, Glob. Prod. Dev. & Supply |
SELL
Payment of exercise price or tax liability
|
Direct |
1,196
-18.31%
|
$62,192
$52.99 P/Share
|
|
Apr 01
2024
|
Karin Shanahan EVP, Glob. Prod. Dev. & Supply |
BUY
Exercise of conversion of derivative security
|
Direct |
3,306
+33.6%
|
-
|
|
Mar 10
2024
|
Adam Lenkowsky EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,323
-26.04%
|
$229,119
$53.79 P/Share
|
|
Mar 10
2024
|
Adam Lenkowsky EVP, Chief Commercial Officer |
SELL
Other acquisition or disposition
|
Direct |
4,569
-16.83%
|
-
|
|
Mar 10
2024
|
Adam Lenkowsky EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,016
+41.58%
|
-
|
|
Mar 10
2024
|
Sandra Leung EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
16,660
-1.58%
|
$882,980
$53.79 P/Share
|
|
Mar 10
2024
|
Sandra Leung EVP, General Counsel |
SELL
Other acquisition or disposition
|
Direct |
14,153
-1.29%
|
-
|
|
Mar 10
2024
|
Sandra Leung EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
46,784
+4.01%
|
-
|
|
Mar 10
2024
|
Robert M Plenge EVP, Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,965
-5.92%
|
$104,145
$53.79 P/Share
|
|
Mar 10
2024
|
Robert M Plenge EVP, Chief Research Officer |
SELL
Other acquisition or disposition
|
Direct |
2,789
-6.77%
|
-
|
|
Mar 10
2024
|
Robert M Plenge EVP, Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,143
+18.16%
|
-
|
|
Mar 10
2024
|
Ahn Amanda Poole EVP, Chief Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,375
-29.27%
|
$72,875
$53.79 P/Share
|
|
Mar 10
2024
|
Ahn Amanda Poole EVP, Chief Human Resources |
SELL
Other acquisition or disposition
|
Direct |
1,659
-19.04%
|
-
|
|
Mar 10
2024
|
Ahn Amanda Poole EVP, Chief Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
5,458
+45.43%
|
-
|
|
Mar 10
2024
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
13,649
-7.14%
|
$723,397
$53.79 P/Share
|
|
Mar 10
2024
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
SELL
Other acquisition or disposition
|
Direct |
11,705
-5.19%
|
-
|
|
Mar 10
2024
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
38,388
+14.2%
|
-
|
|
Mar 10
2024
|
Phil M Holzer SVP and Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,389
-3.69%
|
$73,617
$53.79 P/Share
|
|
Mar 10
2024
|
Phil M Holzer SVP and Controller |
SELL
Other acquisition or disposition
|
Direct |
1,682
-3.94%
|
-
|
|
Mar 10
2024
|
Phil M Holzer SVP and Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
5,520
+11.14%
|
-
|
|
Mar 10
2024
|
Cari Gallman EVP, Corporate Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
696
-20.63%
|
$36,888
$53.79 P/Share
|
|
Mar 10
2024
|
Cari Gallman EVP, Corporate Affairs |
SELL
Other acquisition or disposition
|
Direct |
839
-15.09%
|
-
|
|
Mar 10
2024
|
Cari Gallman EVP, Corporate Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
2,761
+38.11%
|
-
|
|
Mar 10
2024
|
Lynelle Hoch President, Cell Therapy Org. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,308
-35.18%
|
$69,324
$53.79 P/Share
|
|
Mar 10
2024
|
Lynelle Hoch President, Cell Therapy Org. |
SELL
Other acquisition or disposition
|
Direct |
1,317
-19.2%
|
-
|
|
Mar 10
2024
|
Lynelle Hoch President, Cell Therapy Org. |
BUY
Exercise of conversion of derivative security
|
Direct |
4,351
+45.6%
|
-
|
|
Mar 10
2024
|
Christopher S. Boerner Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,407
-6.07%
|
$1,028,571
$53.79 P/Share
|
|
Mar 10
2024
|
Christopher S. Boerner Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
16,698
-4.52%
|
-
|
|
Mar 10
2024
|
Christopher S. Boerner Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
54,638
+12.52%
|
-
|
|
Mar 10
2024
|
Giovanni Caforio Executive Chair of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
67,823
-5.03%
|
$3,594,619
$53.79 P/Share
|
|
Mar 10
2024
|
Giovanni Caforio Executive Chair of the Board |
SELL
Other acquisition or disposition
|
Direct |
57,536
-3.79%
|
-
|
|
Mar 10
2024
|
Giovanni Caforio Executive Chair of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
190,130
+10.83%
|
-
|
|
Mar 10
2024
|
David V Elkins EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,522
-3.11%
|
$981,666
$53.79 P/Share
|
|
Mar 10
2024
|
David V Elkins EVP, Chief Financial Officer |
SELL
Other acquisition or disposition
|
Direct |
19,448
-2.98%
|
-
|
|
Mar 10
2024
|
David V Elkins EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
64,326
+8.75%
|
-
|
|
Feb 01
2024
|
Gregory Scott Meyers EVP, Chief Digital & Tech Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
754
-12.48%
|
$36,192
$48.67 P/Share
|
|
Feb 01
2024
|
Gregory Scott Meyers EVP, Chief Digital & Tech Off. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,543
+29.63%
|
-
|
|
Dec 05
2023
|
Christopher S. Boerner Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+2.36%
|
$98,000
$49.78 P/Share
|
|
Dec 02
2023
|
Christopher S. Boerner Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,350
-1.65%
|
$67,500
$50.1 P/Share
|
|
Dec 02
2023
|
Christopher S. Boerner Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,638
+3.12%
|
-
|
|
Dec 02
2023
|
David V Elkins EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,730
-2.16%
|
$186,500
$50.1 P/Share
|